<DOC>
	<DOCNO>NCT00900809</DOCNO>
	<brief_summary>NK cell patient malignant disease often functionally impair . Their function fully restore ex vivo expansion cytokine activation . In addition , vivo administration cytokine expand NK cell expand polyclonal T cell tumor specificity know effect . The utilization Neukoplast™ , form adoptive immunotherapy , offer several advantage . Neukoplast™ represent uniform cell population well-characterized immunophenotype , confirm strong anti-tumor activity easy grow expand culture , make available large number therapeutic delivery .</brief_summary>
	<brief_title>QUILT-3.018 : Neukoplast™ ( NK-92 ) Treatment Refractory Relapsed Acute Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Patients refractory/relapse acute myeloid leukemia . Patients must receive radiotherapy , chemotherapy ( exception hydroxyurea must discontinue 72 hour prior therapy ) biological therapy within precede 2 week plan first Neukoplast™ cell infusion must recover adverse event due prior administer agent Assessable disease measure laboratory bone marrow examination Age : Eighteen year old Performance status : ECOG ≤ 2 ( Appendix A ) Serum creatinine &lt; 2 X upper limit normal Aspartate aminotransferase ( AST ) &lt; 5 X upper limit normal Alanine aminotransferase ( ALT ) &lt; 5 X upper limit normal Total bilirubin &lt; 3X upper limit normal Activated partial thromboplastin time ( PTT ) &lt; 2.5 X upper limit normal Patients must leave ventricular ejection fraction ( LVEF ) ≥45 % Females childbearing potential must negative pregnancy test subject must agree use effective method contraception two week last infusion Neukoplast™ Ability give inform consent Life expectancy great 3 month Note : many eligible patient pancytopenic secondary disease prior therapy hematologic abnormality use criterion entry exclusion . Patients acute promyelocytic leukemia Symptomatic central nervous system ( CNS ) involvement History congestive heart failure Evidence severe uncontrolled systemic disease ( e.g. , unstable uncompensated respiratory , hepatic , renal , cardiac disease ) . Uncontrolled , lifethreatening infection respond antimicrobial therapy ECOG performance status &gt; 2 ( Appendix A ) Hepatitis B C HIV positive serology History psychiatric disorder may compromise compliance protocol allow appropriate inform consent Patient may receive investigational agent Patient receive systemic anticoagulation ( e.g. , warfarin , intravenous heparin . Low dose prophylactic anticoagulation allow ) Patient undergone autologous allogeneic stem cell transplantation Concurrent malignancy solid tumor . Exception : Subjects diseasefree 5 year , subject history completely resect nonmelanoma skin cancer successfully treat situ carcinoma eligible . Subjects second malignancy indolent definitively treat may enrol . Pregnant lactate female .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Neukoplast™</keyword>
	<keyword>NK-92</keyword>
	<keyword>Refractory</keyword>
	<keyword>Refractory Relapsed Acute Myeloid Leukemia</keyword>
</DOC>